OpSens Inc. closing of $28.75 million bought deal public offering

OpSens Inc. completed a $28.75 million bought deal public offering. OpSens issued an aggregate of 15,972,222 common shares at a price of $1.80 per common share, including 2,083,222 common shares issued pursuant to the exercise in full of the over-allotment option granted to the underwriters. The common shares were offered by way of a short form prospectus filed in all provinces of Canada in accordance with Regulation 44-101 respecting Short Form Prospectus Distributions and in the U.S. on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended. The offering was conducted by a syndicate of underwriters led by Stifel Nicolaus Canada Inc.

OpSens, which is a corporation whose common shares are listed on the Toronto Stock Exchange, is a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology. OpSens is also involved in industrial activities in developing, manufacturing and installing innovative fiber optic sensing solutions for critical applications.

Stein Monast LLP acted for OpSens Inc. in the various necessary stages for the completion of its offering with a legal team including
Richard Provencher,
Pierre-Olivier Plante,

Odette St-Laurent,
Emmanuelle-Salambo Deguara.

Davies Ward Phillips & Vineberg LLP acted for the underwriting syndicate, with a team composed of
Olivier Désilets
,
Amélie Doyon,

Jesse Boretsky.